The JN.1 coronavirus variant has risen rapidly to an estimated 39% to 50% of circulating SARS-CoV-2 variants in the United States, according to a Centers for Disease Control and Prevention update released Friday. The World Health Organization this week separately classified JN.1 as a variant of interest because of its rapid spread, while assessing the additional global public-health risk as low.

The rapid increase does not by itself mean JN.1 causes more severe illness. CDC says existing vaccines, diagnostic tests and antiviral treatments are expected to continue working against the variant, and the agency has not identified evidence that JN.1 poses a greater health risk than other recently circulating lineages. The main signal at this stage is growth: JN.1 is increasing faster than competing variants.

A descendant of BA.2.86 becomes a distinct variant of interest

JN.1 descends from BA.2.86, a lineage that attracted attention earlier this year because it carried a large number of changes in the spike protein compared with previous Omicron descendants. JN.1 is closely related to BA.2.86 but carries an additional spike mutation. WHO’s initial risk evaluation says the variant’s proportion has risen quickly in multiple countries and that its growth advantage warrants separate monitoring.

WHO had previously tracked JN.1 within the BA.2.86 family. On Dec. 18 it designated JN.1 independently as a variant of interest, a classification used for lineages with genetic changes and epidemiological characteristics that merit enhanced surveillance. A variant of interest is not the same as a variant of concern; the latter category would imply stronger evidence of substantial public-health impact.

The agency’s Dec. 22 epidemiological update notes rising SARS-CoV-2 activity in some regions during the Northern Hemisphere respiratory-virus season. JN.1’s competitive advantage may reflect increased transmissibility, immune escape or a combination, but the available evidence does not yet establish the precise mechanism.

U.S. estimates nearly double in two weeks

CDC’s Dec. 22 estimate places JN.1 at approximately 39% to 50% of variants circulating nationally for the two-week period ending Dec. 23. That is a sharp increase from an estimated 15% to 29% two weeks earlier. The agency’s respiratory-virus update places the variant’s growth in the context of rising winter activity from COVID-19, influenza and respiratory syncytial virus.

An earlier CDC JN.1 update on Dec. 8 described the lineage as a small but quickly expanding share of U.S. cases. The acceleration since then is consistent with a substantial transmission advantage over other circulating lineages, although variant-percentage estimates are modeled from genomic surveillance and carry uncertainty ranges.

CDC’s Dec. 22 data snapshot also underscores that variant prevalence is only one part of risk assessment. Hospitalizations, emergency-department visits, deaths and wastewater trends help determine whether increased viral circulation is translating into more severe population-level outcomes.

Severity remains the critical unanswered question

Neither WHO nor CDC currently reports evidence that JN.1 causes more severe disease than other recent variants. That conclusion is provisional. A rapidly growing lineage can increase absolute numbers of infections — and therefore hospitalizations — even if the risk to an individual infected person is unchanged or lower.

WHO’s low additional-risk assessment reflects several factors: population immunity from vaccination and prior infection remains widespread, available vaccines are expected to provide protection against severe disease, and there is no clear signal of increased clinical severity attributable to JN.1. Laboratory and real-world data will continue to be evaluated as the variant spreads.

CDC similarly says existing tests and treatments remain effective. Antigen and molecular tests target viral characteristics that are not expected to be invalidated by JN.1’s mutations. Antiviral drugs such as nirmatrelvir-ritonavir and remdesivir act through mechanisms that remain relevant to the new lineage, based on current evidence.

Updated vaccines remain the central preventive tool

The United States shifted this fall to updated monovalent COVID-19 vaccines targeting the XBB.1.5 lineage. JN.1 is genetically different, but immune responses generated by updated vaccination are expected to retain cross-protection, particularly against severe disease. CDC continues to recommend updated vaccination for people age six months and older under the schedule applicable to their age and health status.

The agency also continues to emphasize layered measures for people at elevated risk, including improving indoor ventilation, staying home when ill, testing when symptoms or exposure warrant, and seeking treatment promptly for those who qualify. These recommendations do not change because of the JN.1 designation.

Reuters reported that CDC views the rapid growth as evidence that JN.1 may be more transmissible or better able to evade existing immunity than competing variants. That advantage is an epidemiological observation rather than proof of greater virulence.

Variant surveillance is now operating in a different phase of the pandemic

The JN.1 rise illustrates how SARS-CoV-2 continues to evolve even though the federal and global COVID-19 emergency declarations have ended. Public-health agencies are no longer responding to every new lineage with emergency measures; instead, they combine genomic surveillance with clinical-severity and health-system indicators to determine whether a variant changes the risk environment materially.

WHO’s classification provides a framework for international laboratories and health agencies to share data and examine the variant’s behavior. Contemporary reporting on the WHO decision emphasized both sides of the message: JN.1 is spreading quickly enough to warrant separate attention, but the evidence available this week does not justify treating it as a new level of global health threat.

That distinction is important during a winter season in which several respiratory viruses are circulating simultaneously. A larger share of COVID-19 caused by JN.1 does not necessarily mean a proportionate rise in severe outcomes, but it can contribute to overall respiratory-disease burden if total infections increase.

As of Dec. 23, the best-supported conclusion is therefore measured. JN.1 has become the fastest-growing and likely most common SARS-CoV-2 lineage in the United States, prompting WHO to elevate its surveillance status. Existing vaccines, tests and treatments are expected to remain useful, and there is no demonstrated increase in severity. The coming weeks of hospitalization, laboratory and epidemiological data will determine whether that risk assessment needs to change.